O
Oncolytics Biotech Inc. (ONCY)
NCM – Real Time Price. Currency in USD
0.90
-0.00 (-0.03%)
At close: May 12, 2026, 4:00 PM EDT
0.90
+0.00 (0.02%)
Pre-market: May 13, 2026, 5:30 AM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
0.90
-0.00 (-0.03%)
At close: May 12, 2026, 4:00 PM EDT
0.90
+0.00 (0.02%)
Pre-market: May 13, 2026, 5:30 AM EDT
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (“GI”) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in San Diego, California.
| Name | Position |
|---|---|
| Dr. Thomas C. Heineman M.D., Ph.D. | Chief Medical Officer |
| Jon Patton | Director of Investor Relations & Communication |
| Mr. Andrew P. Aromando | Chief Business Officer |
| Mr. Jared Kelly J.D., L.L.M. | CEO & Director |
| Mr. John McAdory | Executive VP of Strategy & Operations |
| Mr. John Mark Lievonen B.B.A., CM, F.C.A., FCPA, LLD, M.B.A. | Consultant |
| Mr. Kirk J. Look C.A., CPA | Chief Financial Officer |
| Ms. Allison Hagerman P.Eng., P.M.P. | Chief Technology Officer |
| Yujun Wu | VP & Head of Biostatistics |
| Date | Type | Document |
|---|---|---|
| 2026-05-04 | 8-K | oncy-20260504.htm |
| 2026-04-27 | 8-K | oncy-20260427.htm |
| 2026-04-08 | F-10POS | tm2610715d24_f10pos.htm |
| 2026-04-08 | AW | tm2610715d33_aw.htm |
| 2026-04-06 | F-10POS | tm2610715-8_f10pos.htm |
| 2026-04-06 | 8-K | tm2610715d2_8k.htm |
| 2026-04-01 | POS AM | tm2610685d1_posam.htm |
| 2026-04-01 | F-10POS | tm2610685d13_f10pos.htm |
| 2026-04-01 | CORRESP | filename1.htm |
| 2026-03-30 | 10-K | oncy-20251231.htm |